Ligand ID: C04 Drugbank ID: DB00671(Cefixime) Indication:For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-lactamase positive), and S. pyogenes, (3) pharyngitis and tonsillitis caused by S. pyogenes, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains). |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 1ssk | NUCLEOCAPSID PROTEIN (SARSr-CoV) | 3 / 3 | GLY A 49GLU A 114THR A 113 | 0.97A | 20.71 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 1wnc | E2 GLYCOPROTEIN (SARSr-CoV) | 3 / 3 | GLY B 928GLU C1163THR B 923 | 1.16A | 22.75 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 1zv8 | E2 GLYCOPROTEIN (SARSr-CoV) | 3 / 3 | GLY I 28GLU J 15THR I 23 | 1.26A | 15.43 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 2ajf | ACE2 (Homosapiens) | 3 / 3 | GLY A 214GLU A 571THR A 567 | 1.31A | 15.17 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 2beq | SPIKE GLYCOPROTEIN (SARSr-CoV) | 3 / 3 | GLY C 928GLU F1164THR C 923 | 1.27A | 11.66 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 2cjr | NUCLEOCAPSID PROTEIN (SARS-COVTW1) | 3 / 3 | GLY D 285GLU D 281THR D 283 | 1.24A | 22.41 | None | ||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 10 | TYR C 356GLY C 326ASN C 330PHE C 361LEU E 374 | 1.71A | 19.02 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 2gib | NUCLEOCAPSID PROTEIN (SARSr-CoV) | 3 / 3 | GLY B 285GLU B 281THR B 283 | 1.07A | 22.09 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 2w2g | NSP3 (SARSr-CoV) | 3 / 3 | GLY B 572GLU B 587THR B 584 | 1.65A | 18.80 | None | ||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 2xyq | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 10 | PHE A 149TYR A 152GLY A 155PHE A 150LEU A 180 | 1.69A | 19.30 | SAH A1293 (-4.6A)NoneNoneNoneNone | ||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 2xyv | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 10 | PHE A 149TYR A 152GLY A 155PHE A 150LEU A 180 | 1.71A | 19.30 | SAH A1300 (-4.5A)NoneNoneNoneNone | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 3bgf | F26G19 FAB (Musmusculus) | 3 / 3 | GLY B 106GLU C 38THR C 43 | 0.98A | 20.80 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 3d0h | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 3 / 3 | GLY A 214GLU A 571THR A 567 | 1.28A | 14.99 | None | ||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 3d0i | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 10 | TYR E 438TYR E 436GLY E 434ASN E 435ARG E 479 | 1.78A | 21.16 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 3ee7 | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 3 / 3 | GLY C 93GLU C 68THR A 62 | 0.89A | 20.69 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 3i6g | HLA, A-2 (Homosapiens) | 3 / 3 | GLY A 175GLU A 177THR A 178 | 1.05A | 22.26 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 3i6l | BETA-2-MICROGLOBULIN (Homosapiens) | 3 / 3 | GLY E 18GLU E 74THR E 73 | 1.19A | 18.79 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 3 / 3 | GLY A 109GLU C 290THR A 111 | 0.84A | 19.27 | None | ||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 3r24 | 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 10 | PHE A 149TYR A 152GLY A 155PHE A 150LEU A 180 | 1.72A | 19.42 | SAM A 302 ( 4.8A)NoneNoneNoneNone | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 3 / 3 | GLY A 214GLU A 571THR A 567 | 1.19A | 14.99 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 4ovz | PAPAIN-LIKEPROTEINASE (SARS-COVUrbani) | 3 / 3 | GLY B 164GLU B 168THR B 169 | 0.96A | 20.67 | P85 B 902 ( 3.5A)DMS B 906 ( 3.4A)None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 5c8s | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 3 / 3 | GLY B 123GLU B 132THR B 131 | 0.99A | 15.74 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 5c8t | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 3 / 3 | GLY D 123GLU D 132THR D 131 | 0.95A | 15.71 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 3 / 3 | GLY C 123GLU C 132THR C 131 | 0.91A | 16.04 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 5x29 | ENVELOPE SMALLMEMBRANE PROTEIN (SARSr-CoV) | 3 / 3 | GLY C 10GLU D 8THR D 9 | 1.12A | 21.88 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 5y3q | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 3 / 3 | GLY A 164GLU A 168THR A 169 | 1.18A | 20.75 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 6acj | ACE2SPIKE GLYCOPROTEIN (Homosapiens;SARSr-CoV) | 3 / 3 | GLY C 488GLU D 329THR C 486 | 1.43A | 9.48 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 6ack | ACE2 (Homosapiens) | 3 / 3 | GLY D 214GLU D 571THR D 567 | 1.32A | 15.17 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 6iex | MHC CLASS I ANTIGEN (Homosapiens;SARSr-CoV) | 3 / 3 | GLY A 100GLU C 2THR C 3 | 1.20A | 21.58 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 6m1d | ACE2 (Homosapiens) | 3 / 3 | GLY D 214GLU D 571THR D 567 | 1.15A | 10.32 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 6m1d | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 3 / 3 | GLY C 215GLU C 456THR C 459 | 1.43A | 11.97 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 3 / 3 | GLY A 587GLU A 593THR A 585 | 1.59A | 9.57 | None | ||
![]() | 4KOU_A_C04A207_1 (UNCHARACTERIZEDPROTEIN) | 6nus | NSP12 (SARSr-CoV) | 3 / 3 | GLY A 616GLU A 802THR A 801 | 1.22A | 10.01 | None | ||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 10 | TYR H 52PRO H 53TYR H 32GLY H 101LEU H 4 | 1.68A | None | |||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 10 | TYR B 52PRO B 53TYR B 32GLY B 101LEU B 4 | 1.71A | None | |||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 10 | TYR B 52PRO B 53TYR B 32GLY B 101LEU B 4 | 1.67A | None | |||
![]() | 4KOU_A_C04A206_1 (UNCHARACTERIZEDPROTEIN) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 10 | TYR H 52PRO H 53TYR H 32GLY H 101LEU H 4 | 1.68A | None |